CancerIQ Aims to Close Gap in Cancer Risk Assessment with Personalized Patient Education

Strategic Insights -

CancerIQ, a healthcare technology company, is addressing a critical gap in cancer risk assessment by providing patients with "hyper-personalized" patient education, engagement, and navigation support. The company's focus is on helping patients take the next crucial step in cancer prevention, particularly in identifying those at high risk for cancer. With a precision health platform, CancerIQ aims to make cancer prevention and early detection more accessible and effective.

Key Takeaways:

  • CancerIQ's precision health platform provides healthcare providers with a comprehensive patient data map, automatically mapping it to the latest evidence-based guidelines, and designing tailored cancer prevention plans.
  • The platform is designed to streamline the genetic counseling and testing process, helping to improve genetic testing uptake.
  • CancerIQ's new capabilities include patient navigation support, personalized education, and navigation, aiming to drive sustained follow-through on supplemental screenings that detect cancer earlier.
  • The company has identified barriers to supplemental breast MRI, including high costs, lack of insurance coverage, anxiety, poor communication with providers, and lack of support.
  • CancerIQ has implemented its platform in over 300 clinic locations and works with more than 65 health systems, with a focus on resource-limited community sites and leading academic cancer centers.
  • The company's platform equips providers with the ability to identify patients' lifetime and hereditary cancer risks accurately, offering personalized cancer prevention strategies and early detection plans.

Statistics:

  • According to the American Cancer Society, women at high risk for breast cancer should get an annual breast MRI screening in addition to a mammogram.
  • Studies show that only about half of high-risk women reported their doctor recommending a breast MRI screening, and only 32% received a breast MRI.
  • CancerIQ's platform can create referral letters to help providers secure timely insurance approval, reducing administrative friction.
  • The platform tracks patients in real-time from eligibility to appointment completion, aiming to democratize access to screening.

Sources:

  • Fierce Healthcare
  • American Cancer Society
  • CancerIQ's website